SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Supplements/Fatty Acid

EPA-Only Omega-3

Pure EPA reduces residual cardiovascular risk on statins.

Cardiovascular HealthMood & Anxiety

Overview

Pure EPA reduces residual cardiovascular risk on statins.

Natural sources
    Common forms

      Forms & variants of Omega-3 (EPA/DHA)

      Different chemical forms of Omega-3 (EPA/DHA) behave differently. Browse each form's mechanism, bioavailability, and best-use context.

      Parent
      Omega-3 (EPA/DHA)

      Marine long-chain omega-3s — the most-studied anti-inflammatory and cardiovascular nutrient.

      Prenatal DHA
      DHA (Prenatal)

      Critical fatty acid for fetal brain and retinal development.

      Mechanism of action

      Lowers triglycerides via PPAR-α activation and reduces vascular inflammation.

      Pathways

        Effects on the body

        Organ system effects

        Evidence-based benefits

        Reduces major CV events in high-risk patients (REDUCE-IT)

        Strong evidence

        Potential side effects

        Common
        • · Fishy aftertaste
        • · Bleeding tendency
        Rare
        • · Atrial fibrillation
        Serious

          Drug interactions

          No notable interactions reported.

          Supplement interactions

          Pairs well with

          None listed.

          Avoid combining with

          No specific avoidances listed.

          Dosing & bioavailability

          Typical dose
          2–4 g/day (Rx)
          With food?
          With food

          Where to buy

          Affiliate-style search links to reputable retailers. We don't endorse specific brands — verify third-party testing (USP, NSF, Informed Sport) before purchase.

          Fatty Acid
          EPA-Only Ome…
          Amazon
          Wide selection · fast shipping
          Fatty Acid
          EPA-Only Ome…
          iHerb
          Global delivery · curated brands
          Fatty Acid
          EPA-Only Ome…
          Thorne
          Practitioner-grade · NSF tested

          Scientific evidence (8)

          RCTN Engl J Med · 2019

          REDUCE-IT trial

          Bhatt DL, et al.

          5-year DB-RCT in 8179 high-risk patients on statins.

          Key findings

          4 g/day icosapent ethyl reduced MACE by 25%.

          Open study
          Systematic reviewPubMed (NLM) · 1970

          PubMed: EPA-Only Omega-3 — Reduces major CV events in high-risk patients

          Live PubMed search

          Live results for "EPA-Only Omega-3 Reduces major CV events in high-risk patients" across the PubMed/MEDLINE peer-reviewed index.

          Key findings

          Opens current human and preclinical literature matching EPA-Only Omega-3 and "Reduces major CV events in high-risk patients". Filter by RCT, meta-analysis, or year on the results page.

          Open study
          Systematic reviewPubMed (NLM) · 1970

          PubMed: EPA-Only Omega-3 — randomized controlled trial

          Live PubMed search

          Live results for "EPA-Only Omega-3 randomized controlled trial" across the PubMed/MEDLINE peer-reviewed index.

          Key findings

          Opens current human and preclinical literature matching EPA-Only Omega-3 and "randomized controlled trial". Filter by RCT, meta-analysis, or year on the results page.

          Open study
          Systematic reviewPubMed (NLM) · 1970

          PubMed: EPA-Only Omega-3 — meta-analysis

          Live PubMed search

          Live results for "EPA-Only Omega-3 meta-analysis" across the PubMed/MEDLINE peer-reviewed index.

          Key findings

          Opens current human and preclinical literature matching EPA-Only Omega-3 and "meta-analysis". Filter by RCT, meta-analysis, or year on the results page.

          Open study
          Systematic reviewPubMed (NLM) · 1970

          PubMed: EPA-Only Omega-3 — pharmacokinetics

          Live PubMed search

          Live results for "EPA-Only Omega-3 pharmacokinetics" across the PubMed/MEDLINE peer-reviewed index.

          Key findings

          Opens current human and preclinical literature matching EPA-Only Omega-3 and "pharmacokinetics". Filter by RCT, meta-analysis, or year on the results page.

          Open study
          Systematic reviewPubMed (NLM) · 1970

          PubMed: EPA-Only Omega-3 — safety adverse events

          Live PubMed search

          Live results for "EPA-Only Omega-3 safety adverse events" across the PubMed/MEDLINE peer-reviewed index.

          Key findings

          Opens current human and preclinical literature matching EPA-Only Omega-3 and "safety adverse events". Filter by RCT, meta-analysis, or year on the results page.

          Open study
          Systematic reviewPubMed (NLM) · 1970

          PubMed: EPA-Only Omega-3 — dose response

          Live PubMed search

          Live results for "EPA-Only Omega-3 dose response" across the PubMed/MEDLINE peer-reviewed index.

          Key findings

          Opens current human and preclinical literature matching EPA-Only Omega-3 and "dose response". Filter by RCT, meta-analysis, or year on the results page.

          Open study
          Systematic reviewGoogle Scholar · 1970

          Google Scholar: EPA-Only Omega-3 — clinical evidence

          Live Scholar search

          Cross-database citation index for EPA-Only Omega-3 as it relates to "clinical evidence".

          Key findings

          Includes preprints, theses, and journal articles. Useful for tracking citation counts and follow-on work.

          Open study
          Educational use only. This profile is not medical advice. Consult a qualified healthcare professional before starting any supplement, especially if you take prescription medication or have a chronic condition.